Stock CRNO B CERENO SCIENTIFIC AB
Add to a list
To use this feature you must be a member
Log inSign up

Cereno Scientific AB

Equities

CRNO B

SE0008241558

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:24:51 2024-04-26 am EDT 		5-day change 1st Jan Change
4.036 SEK +0.15% Intraday chart for Cereno Scientific AB -7.00% -11.78%
Apr. 16 Cereno Scientific AB Approves Election of New Directors CI
Apr. 11 Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Cereno Scientific AB

Cereno Scientific AB Approves Election of New Directors CI
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate MT
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment MT
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014 CI
Cereno Scientific Receives Patent Expansion in Europe MT
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate MT
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH CI
Cereno Scientific Appoints Don De Bethizy as Board of Directors CI
Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH CI
Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH CI
Cereno Scientific AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH CI
Sweden's Cereno Scientific Appoints Chief Medical Officer MT
Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D CI
Cereno Scientific AB Appoints Julia Fransson as Director of Business Development CI
Cereno Scientific AB Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities CI
Cereno Scientific Gets US FDA Approval for Expanded Access to Drug Candidate MT
Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension CI
Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director CI
Cereno Scientific Pens Contact with CordenPharma for Scaled Manufacturing of Hypertension Drug MT
Cereno Scientific Submits Request to the FDA for "Compassionate Use" of CS1 for Treatment of Patients with Rare Disease Pulmonary Arterial Hypertension CI
Cereno Scientific Seeks US FDA Nod for Compassionate Use of Investigational Drug CS1 MT
Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH CI
Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting CI
Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585 CI

Chart Cereno Scientific AB

Chart Cereno Scientific AB
More charts

Company Profile

Cereno Scientific AB is a manufacturer of pharmaceutical preparation. The Company was founded in 1970 and is located in Gothenburg, Sweden.
Sector
Biotechnology & Medical Research
Calendar
2024-05-22 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CERENO SCIENTIFIC AB Stock Cereno Scientific AB
-11.78% 103M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CRNO B Stock
  4. News Cereno Scientific AB
  5. Cereno Scientific Names RLS Global CFO to Same Role